Stock Information

• HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $289
  Thu, Apr 30, 2026 6:31 AM
• RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $252
  Tue, Apr 28, 2026 10:24 AM
• Ligand Pharmaceuticals Incorporated (LGND) XOMA Royalty Corporation - M&A Call - Slideshow
  Mon, Apr 27, 2026 4:00 PM
• Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million
  Mon, Apr 27, 2026 1:18 PM
• Earlier Monday, Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.00-$9.00 to $8.50-$9.50 vs $9.40 Est; Raises FY2026 Sales Guidance from $245M-$285M to $270M-$310M vs $266.714M Est
  Mon, Apr 27, 2026 1:07 PM
• XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday
  Mon, Apr 27, 2026 10:20 AM
• Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript
  Mon, Apr 27, 2026 10:01 AM
• Ligand Pharmaceuticals Incorporated : To Acquire XOMA Royalty
  Mon, Apr 27, 2026 7:26 AM
• Ligand Pharmaceuticals To Acquire XOMA Royalty For $39.00 Per Share In Cash, Ligand Raises FY2026 Adj. EPS Guidance To $8.50-9.50 And Expects The Transaction To Be Accretive By $1.50 Per Share To Adj. EPS In 2027
  Mon, Apr 27, 2026 7:06 AM
• Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
  Mon, Apr 27, 2026 7:01 AM

Financial data not available